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Mechanism of angiotensin converting enzyme inhibitor-related anemia
in renal transplant recipients. To delineate the pathogenesis of the
reduction in hemoglobin occurring in renal transplant patients treated
with angiotensin converting enzyme inhibitors (ACEI) and azathioprine
(AZA) a controlled, prospective trial of ACEI withdrawal was conducted.
The ACEI was replaced by nifedipine or clonidine in 15 kidney transplant
patients immunosuppressed with AZA and prednisone (enalapril in 14
and captopril in 1). Before and during 10 to 12 weeks after withdrawal of
the ACET, AZA metabolites, renal function parameters and hematologi-
cal parameters including erythropoietin and reticulocytes were evaluated.
Enalaprilat levels were measured and compared with 15 similar patients
matched for transplant function and enalapril dosage immunosuppressed
with cyclosporine and prednisone. AZA metabolites did not differ signif-
icantly in the presence or absence of the ACEI. Enalaprilat levels also
showed no significant difference between the two patient groups treated
with AZA or cyclosporine. Hematocrit and hemoglobin increased signif-
icantly from 37.5 6.4 to 39.7 3.6% (mean SD, P = 0.02) and 12.8
2.2 to 13.5 1.2 g/dl, P = 0.04, respectively, 10 to 12 weeks after ACEI
treatment had been discontinued. Simultaneously numbers of reticulo-
cytes and erythropoietin concentrations rose significantly after 2, 4 and 10
weeks, with a peak at two weeks (from 14.1 3.8 to 20.6 8.O%, P <
0.05 and from 14.3 12.4 to 29.3 54.5 mU/mi, P < 0.05, respectively).
In conclusion, ACEI-related anemia in renal transplant recipients seems
to be due to the erythropoietin-lowering effect of this group of drugs. A
pharmacokinetic interaction between AZA and enalapril is not likely since
plasma enalaprilat levels were independent of the immunosuppressive
regimen and AZA metabolite levels were unchanged in the presence and
absence of the ACEI. Several mechanisms by which angiotensin convert-
ing enzyme blockade may cause a decrease in circulating erythropoietin
are discussed.
Angiotensin converting enzyme inhibitors (ACEI) have been in
use for years in the treatment of hypertension and cardiac failure
and their actions and side effects have been reviewed extensively
[1, 2]. But, apart from a letter in The Lancet [3] describing a
decrease in hematocrit in a group of hypertensives and healthy
volunteers treated with MK-421 (enalapril), anemia is not listed as
a typical side effect of this group of drugs [1, 2, 4]. In renal
transplant patients several groups, including our own [5—7], have
shown that treatment with ACEI can lead to a significant decline
in hematocrit and hemoglobin. ACE! have also been used sue-
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cessfully in the treatment of erythrocytosis in these patients [8, 9].
We [7] and others [10] have also shown that the concomitant use
of AZA as immunosuppressant probably contributes to the ACET
related anemia in this population. Furthermore, it has been shown
that AZA-treated patients are less likely than cyclosporine-
treated patients to develop post-transplant erythrocytosis [11].
Studies on the mechanism of ACE! related anemia have yielded
conflicting results. While some researchers reported a decline of
erythropoietin (EPO) levels in ACEI treated patients [9, 12—14]
and healthy volunteers [15], others did not see such an effect
[16—18]. Since essentially all reports of ACEI related anemia were
on hemodialysis or renal transplant patients, we hypothesized that
abnormally high enalaprilat levels, either caused by impaired
renal excretion or, in the case of a well functioning renal
transplant, by an interaction with AZA could explain the relatively
high incidence of this complication in that group of patients.
Since isolated cases of anemia have also been seen in patients
treated with AZA alone [19, 20] it also seemed conceivable that
enalapril may induce anemia by affecting AZA bioavailability or
metabolite levels.
To clarify the mechanism leading to anemia in these patients
and to find out if there was a pharmacokinetic interaction between
AZA and enalapril, we undertook a prospective trial of with-
drawal of the ACEI in a group of 15 AZA-treated renal transplant
patients. Transplant function, a number of hematological param-
eters, including EPO plasma levels, enalaprilat concentrations in
plasma and urine, and AZA metabolites in red blood cells, plasma
and urine were determined before and several times during 10 to
12 weeks after discontinuation of the ACEI. As a control,
enalaprilat plasma and urine levels were also determined in a
group of 15 renal transplant patients taking cyclosporine as
immunosuppressant.
Methods
The study protocol was approved by the local ethics committee
and all patients gave written informed consent. From the records
of our outpatient renal transplant clinic we identified 18 adult
patients who were treated with AZA and enalapril and one
patient who took AZA and captopril. The reason for the ACE!
treatment was hypertension in all cases. Four patients in the
former group were unwilling to participate in the study and were
therefore excluded. No other exclusions were made.
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All patients took AZA once daily in doses ranging from 0.8 to
2.7 mg/kg/day and enalapril (or captopril) once or twice daily
(dose range enalapril 0.06 to 0.28, captopril 1.02 mg/kg/day).
Patients came to the clinic on two separate occasions before
enalapril was replaced by clonidine or nifedipine. Two separate
12-hour urine samples were collected the day before the blood
drawing. A first blood sample was drawn at 8.00 a.m. to determine
trough levels of AZA and enalaprilat, followed by oral adminis-
tration of both drugs. Three hours later, approximately coinciding
with peak plasma concentrations of 6-mercaptopurine, the main
plasma metabolite of AZA and with maximal plasma concentra-
tions of enalaprilat, the active diacid metabolite of enalapril,
another blood sample was drawn. Blood samples for determina-
tion of AZA metabolites were drawn using lithium-heparin con-
taining tubes, and samples for enalaprilat plasma levels were
collected into sodium-heparin containers.
The same day, the following parameters were determined by
standard clinical laboratory methods: sodium, potassium, calcium,
inorganic phosphate, creatinine, urea, complete blood count
(CBC) including reticulocytes, ferritin, iron binding capacity,
haptoglobin, LDH, vitamin B-12, and folate.
Two weeks and four weeks later blood samples were analyzed
for renal function parameters, CBC and EPO. Ten to 12 weeks
after withdrawal of enalapril, the analysis of AZA metabolites was
repeated twice and the above mentioned laboratory parameters
were again determined.
Analytical procedures
For determination of 6-thioguanine nucleotides in red blood
cells (RBC) these were washed twice in Hank's balanced salt
solution and stored frozen at —20°C as well as the remaining
plasma. Sample preparation for red blood cells and plasma
included a solid phase extraction using a mercurial cellulose resin
modified after Lavi and Holcenberg [211. Thereafter, 6-thiogua-
nine nucleotides as well as thiouric acid and 6-mercaptopurine
were measured by HPLC using 4-thiouridine-5-monophosphate
for internal standard as described by Weller et al [22]. Recovery of
6-thioguanosin-di-phosphate after extraction came to 73.8% and
to 93.8% for 6-thioguanosin-tri-phosphate with a coefficient of
variation below 10%. The lower limit of detection of 6-thiogua-
nine nucleotides was 30 pmol/100 pJ RBC, the intraassay coeffi-
cient of variation over the range from 50 to 1000 pmol/100 j.d
RBC varied between 5.4 and 8.9%, the interassay variation came
to 6.7 to 11.4%. The recovery of 6-mercaptopurine and thiouric
acid was determined to 65% and 69%, respectively, with variation
coefficients also below 10%. The lower limit of detection was 5
ng/ml for both, 6-mereaptopurine and thiouric acid. Inter- and
intraassay coefficients of variation were below 12%.
Enalaprilat plasma and urine levels were analyzed by radioim-
munoassay as described [23, 24] using material kindly provided by
Merck, Sharp and Dohme (Rahway, NJ, USA). The lower limit of
detection was 0.2 ng/ml, inter- and intraassay coefficients of
variation were 10.7 and 7.6%, respectively, for an enalaprilat
concentration of 25 ng/ml.
EPO was measured by ELISA (Medac, Hamburg, Germany).
Creatininc clearance, not corrected for body surface area, and
fractional sodium excretion were calculated for each of the two
visits at the beginning and the end of the study and averaged.
To study the possible influence of AZA on enalaprilat concen-
trations, we analyzed enalaprilat plasma and urine levels in 15
1 65 M 157 1.00
2 60 F 127 1.30
3 39 M 63 1.95
4 29 F 56 1.10
5 45 M 88 2.20
6 53 F 66 1.05
7 43 M 47 1.20
8 53 M 172 1.95
9 52 F 135 1.15
10 33 M 159 1.30
11 32 M 39 2.15
12 35 M 78 5.55
13 42 M 68 1.35
14 53 F 62 1.25
15 59 M 109 3.15
Abbreviations are: E, enalapril; C, captopril.
control patients, matched for enalapril dosage and transplant
function, who were treated with cyclosporine and enalapril.
Statistics
All data are given as mean SD. For statistical evaluation, the
data from the two visits before withdrawal of enalapril were
averaged and compared with the averaged values from the two
visits 10 to 12 weeks later by Wilcoxon matched pairs test. Since
trough plasma samples did not contain measurable concentrations
of 6-mercaptopurine and thiouric acid, only peak concentrations
were used. Due to the long half life of 6-thioguanine in red blood
cells, concentrations pre and post-drug intake were almost iden-
tical at steady state. Therefore, concentrations from all four blood
samples were averaged both before and after replacement of
enalapril.
Correlation analyses were performed by Spearman's test for
rank correlation.
Differences between the AZA group and the cyclosporine
treated patients were evaluated by U-test of Mann/Whitney. All
calculations were done with Instat 2.0 (Graph-Pad software, San
Diego, CA, USA), and P values < 0.05 were considered signifi-
cant.
Results
The basic characteristics of the study group are given in Table
1. A considerable number of long-term transplanted patients had
excellent kidney function. Table 2 shows the laboratory parame-
ters of the 15 patients at the beginning and end of the study. Nine
patients had subnormal hematocrit values (lower level of normal
42% for men and 37% for women [25]), and six patients had no
evidence of anemia. During the study period there was a signifi-
cant increase in hematocrit (from 37.5 6.4 to 39.7 3.6%, P =
0.02) and hemoglobin (from 12.8 2.2 to 13.5 1.2 g/dl, P =
0.04, Table 2) that was largely confined to the anemic patients.
This was accompanied by a significant decrease in ferritin (from
257.40 196.86 to 178.60 139.73 mg/liter, P = 0.04) and,
paradoxically, by an increase in LDH (from 171.20 30.20 to
194.67 40.74 U/liter, P = 0.0003). Diastolic blood pressure rose
Table 1. Characterization of 15 renal transplant patients who were
concomitantly treated with azathioprine and an ACE inhibitor (ACEI)
Patient
No.
Time since
transplant
Age Sex months
Azathioprine ACEI
dose doseCreatinine _____________
mg/dl mg/kg/day
0.86
1.53
2.40
2.08
2.47
1.27
1.97
1.58
2.73
1.60
2.19
0.81
1.77
1.88
2.27
E 0.23
C 1.02
E 0.14
E 0.10
E 0.28
E 0.25
E 0.13
E 0.11
E 0.18
E 0.26
E0.06
E 0.08
E 0.24
E 0.13
E 0.06
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Week 0 Weeks 10—12 pa
Hematocrit % 3754 6.42" 39.72 3.56 0.022
Hemoglobin g/dl 12.76 2.20 13.49 1.16 0.035
Erthrocytes/pl 3.64 0.79 3.78 0.51 NS
Leukocytes/nI 6010 1774 6313 1712 NS
Thrombocytes H13/ni 243 53 238 61 NS
MCVfl 104.66 9.64 105.76 8.13 NS
MCHpg 35.62 3.47 35.96 2.96 NS
Ferritin pg/liter 257.40 196.86 178.60 139.73 0.041
Haptoglobin mg/dl 172.50 102.04 155.00 80.84 NS
LDH U/liter 171.20 30.20 194.64 40.74 0.0003
Vitamin B-12 pg/mi 277.47 158.72 282.67 182.24 NS
Folic acid ng/ml 7.35 2.04 6.86 2.41 NS
Creatinine mg/dl 1.84 1.19 1.88 1.11 NS
Systolic BP mm Hg 143 19 153 19 NS
Diastolic BP mm Hg 87 12 94 12 0.048
Fractional sodium 1.58 0.97 1.82 1.48 NS
excretion
from 87 12 to 94 12 mm Hg (P = 0.05). The other laboratory
parameters showed no significant differences.
Parallel to the rise in hematocrit and hemoglobin EPO levels
and numbers of reticulocytes increased significantly, reaching a
peak value at two weeks after withdrawal of the ACEI (Fig. 1A).
The large standard variation in the EPO levels shown is due
mainly to one patient (Fig. lB has the individual values). This was
the patient with the worst renal function (patient 12 in Table 1),
the highest enalaprilat level (46 nglml) and the most marked
increase in both EPO levels (which increased by 333.79% after 2
weeks) and hematocrit (increasing by 72.33% at the end of the
study). Exclusion of this patient from the analysis did not affect
the significance of our findings. There was a strong positive
correlation between enalaprilat trough concentrations measured
before withdrawal of the drug and the percentage of increase in
hematocrit (r = 0.78, P < 0.01, N = 14), suggesting a dose
dependency of this effect (Fig. 2).
6-Thioguanine-nucleotides in red blood cells showed a large
inter-subject variability ranging from 39 to 654 pmol/100 p.i RBC;
however, intraindividual variability during the observation period
was below 20%. In contrast to the findings of Lennard et al [26],
we found no correlation between the AZA dose per kg body wt
and 6-thioguanine concentrations in RBC (r =
—0.396, P> 0.05;
not shown). 6-Mercaptopurine and thiouric acid in plasma, and
6-thioguanine nucleotides in crythrocytes remained almost un-
changed in the presence or absence of enalapril, although urinary
excretion of 6-mercaptopurine and thiouric acid decreased signif-
icantly from 141 71 to 112 97 ,irg/24 hr (P < 0.05) and from
1778 912 to 1328 748 ig/24 hr (P < 0.05), respectively (Table
3).
We considered it ethically and practically not feasible to change
the immunosuppressive medication of the patients in the study
group in order to assess the possible influence of AZA on
enalaprilat concentrations. Therefore we used a group of enala-
pril-treated renal transplant patients with cyclosporine-based im-
munosuppression as controls. These were matched to the study
group as to creatinine clearance and enalapril dosage. The
average enalapril dose in AZA treated patients was 0.15 0.07
Table 2. Laboratory parameters of 15 renal transplant patients before A
and 10—12 weeks after the end of ACE inhibitor treatment
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Fig. 1. E,ythropoietin (EPO) concentrations and reticulocyte counts of 15
renal transplant patients 2,4, and 10 to 12 weeks after discontinuation of the
ACEJ. A. Mean values 5D. P values were calculated with Wilcoxon
matched pairs statistic. Symbols are: (•) EPO, (U) reticulocytes. B.
Individual values of erythropoietin concentrations in the 15 patients.
mg/kg and in cyclosporine treated patients 0.18 0.07 mg/kg,
creatinine clearance was 71.05 27.80 mI/mm in AZA treated
patients and 80.56 38.35 mI/mm in the cyclosporine group (P>
0.05). We found no statistically significant difference of enalaprilat
levels in plasma and urine between the 14 patients on AZA
compared with the group of 15 patients using cyclosporine (Table
4).
Discussion
Our data support the view that ACEI related anemia, which has
been described mainly in hemodialysis [13, 18] and renal trans-
plant patients [5—7, 27, 28], is caused by a decrease in erythropoi-
etin plasma concentration. A decrease of erythropoietin levels
10
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following ACEI therapy has also been found in patients with renal
insufficiency [121, hemodialysis patients [131, patients with conges-
tive heart failure [141 and normal volunteers [15]. Several of the
studies on the mechanism mediating the hematocrit lowering
effects of ACEI in patients with post-transplant erythrocytosis
seem to point in the same direction. All authors report a
hematocrit-lowering effect of ACEI treatment in these patients,
but only some of them found a significant concomitant reduction
of erythropoietin levels [9, 29, 301. Others found a decrease in the
hormone that failed to reach statistical significance [16, 171.
The reason why an ACEI should lower erythropoietin produc-
tion or increase its degradation is not understood. One hypothesis
put forward by several authors [28, 31] is that ACEIs may lower
EPO production by increasing renal blood flow. This hypothesis is
supported by the findings of Tan and Ratcliffe [32], who showed
that the production of EPO mRNA was not only dependent on
the partial pressure of oxygen but could be enhanced by a
decrease in flow rate in isolated perfused rat kidneys. These
experimental data are in conflict, however, with the results of
Pagel, Jelkmann and Weiss [33] and Kokot and Wiecek [34], who
did not find a significant effect of renal artery stenosis on EPO
production in vivo. Another explanation could be a decrease in
renal oxygen consumption, which is largely determined by sodium
absorption in the proximal tubules [351 that, among other mech-
anisms, is regulated by angiotensin II. Since sodium reabsorption
is decreased by ACEI [361, a decrease in renal oxygen consump-
tion may lead to an increased oxygen availability for the EPO
producing cells. Support for this possibility comes from the
experimental data of Eckhardt, Kurtz and Bauer [37], who
described decreased EPO production after inhibition of proximal
tubular sodium absorption by acetazolamide. We were, however,
unable to detect a significant difference of the fractional excretion
of sodium in the presence or absence of ACET (Table 2), which
niay be due to concomitant diuretic medication. A third possibility
is a direct influence of angiotensin II on EPO production, which
has been shown in experimental animals [38—40]. Interestingly,
suppression of angiotensin II levels has been found in dialysis
patients treated with recombinant EPO for renal anemia, suggest-
Table 3. 6-Thioguanine nucleotide (TGN) levels in red blood cells
(RBCs), 6-mercaptopurinc (MP) and thiouric acid (TUA) levels in
plasma (p) and 24 hour urine (u) before and after withdrawal of the
ACE inhibitor (ACEI)
TGN
pmol/ MP (p) TUA (p) MP (u) TUA (u)
lOOp]
RBCs ng/ml pg/day
With ACEI 277 171 14.8 9.9 398 262 141 71 1778 912
Without 304 194 15.3 9.1 451 253 112 97 1328 748
ACEI
P value NS NS NS < 0.05 < 0.05
Data are mean SD. P values were determined by Wilcoxon matched-
pairs test.
Table 4. Peak and trough concentrations in plasma and 12-hour
urinary excretion of enalaprilat in renal transplant patients taking
azathioprinc (AZA) or cyclosporine (CS)
Trough Peak
_________________________
Urine
__________
ng/rnl mg/12 hr
AZA group 14.53 11.31 34.81 16.13 1.16 0.59(N = 14)
CS group 22.23 15.31 36.70 20.71 1.36 1.13(N = 15)
P value NS NS NS
Data are mean SD. P values were determined by the Mann/Whitney
U-test.
ing a feedback loop between EPO and the renin-angiotensin
system [411.
AZA has been described to increase the amount of ineffective
erythropoiesis [42] that may lead to a greater demand for EPO,
rendering these patients more vulnerable than others for the
EPO-lowe ring effect of ACEIs. Indeed, in patients with congestive
heart failure and normal renal function [14] and in healthy
volunteers [151 it has been shown that, despite a significant decline
in erythropoietin concentrations following ACEI treatment, there
was no measurable effect on hematocrit. In a prospective study
[43] including 12 hypertensive patients with normal renal function
treated with ACEI (the only formal study on this problem in
non-renal patients known to us) it took 18 months until a decrease
of hematocrit and hemoglobin, by 6.1% and 7.6%, respectively,
became detectable. In our original observation [7] the ACEI
related anemia developed in patients whose immunosuppressive
regimen was converted from cyclosporine to AZA and who
continued to take enalapril. Therefore, we suspected a pharma-
cokinetic interaction between the two drugs. Since this kind of
anemia has been seen predominantly in patients with some degree
of renal insufficiency and because most ACEIs are excreted
almost exclusively by the kidney [44], we thought that inappropri-
ately high enalaprilat plasma concentrations might he involved
that, in our patients, might have been caused not by renal
insufficiency but by the concomitant AZA medication. This pos-
sibility now seems to be largely excluded by our finding of similar
enalaprilat levels in patients on AZA as compared to patients
taking cyelosporine. To our knowledge this is the first study
reporting enalaprilat plasma levels in renal transplant patients.
Our data correspond well to the data on enalaprilat levels in
patients with different degrees of renal insufficiency. In accor-
dance with the findings published by Fruncillo and co-workers
I. .. .s
S
0 5 10 15 20 25 30 35 40 45 50
Enalaprilat-trough concentration, ng/ml
Fig. 2. Correlation between the increase in hematocrit (Hct) after with-
drawal of enalapril and plasma enalaprilat trough concentration at the
beginning of the study. Spearman rank correlation analysis, r = 0.78, P <
0.01, N 14.
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Fig. 3. Correlation between enalapril dosage and plasma enolaprilat trough
concentration in patients from the AZA and the cyclosporine group with a
creatinine clearance above 30 mI/mm. Spcarman rank correlation analysis,
r = 0.41, P = 0.03, N = 29.
a significant correlation of enalaprilat dose and plasma level
was only found in patients with a creatinine clearance above 30
mi/mm (r = 0.41, P = 0.03, N = 27, Fig. 3); in patients with lower
clearances we found no correlation between dosage and plasma
level.
Since AZA itself has also been implicated in rare cases of
isolated anemia without evidence for bone marrow suppression
[19,201, and in one published case was found to be due to elevated
thionucleotide levels in red blood cells caused by abnormal AZA
metabolism [46], we also tested the possibility that enalaprilat
might alter AZA bioavailability or metabolism. However, no
significant differences in AZA metabolites with or without coad-
ministration of enalapril were detected. The increased incidence
of ACEI related anemia in patients taking AZA may simply be
due to its antiproliferative action. In the face of the relative rarity
of this side effect of ACEI in patients with normal renal function
it appears that, for their effect on erythropoietin concentrations to
become clinically relevant, another prerequisite must be fulfilled.
This might be uremia or concomitant therapy with AZA.
We conclude that ACEI related anemia is causally linked to the
erythropoietin-lowering effect of this group of drugs. A pharma-
cokinetic interaction between AZA and enalaprilat is unlikely to
be the culprit in the face of essentially unchanged plasma levels of
the major AZA metabolites in the plasma with or without
enalapril comedication and comparable enalaprilat levels in AZA
and cyclosporine treated patients. A likely mechanism explaining
the influence of an ACEI on EPO levels is a feedback between
EPO and the renin-angiotensin system.
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